AdAPT-001, Checkpoint Inhibitor, Immune — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-01 in 2mo
ESTIMATED |
READOUT
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Phase 2 · Solid Tumor, Adult, Cancer |
EpicentRx, Inc. | AdAPT-001, Checkpoint Inhibitor, Immune |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|